Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Summary Report of the OHE/EFPIA Antibacterial Roundtable
1 November 2011
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures…
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
Recent reforms to the National Health Service (NHS) in England include important changes in the regulation of prices for new medicines. From January 2014, the existing…
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing global public health threat, AMR reduces the chances of…
Exploring the Interdependency between Public and Charitable Medical Research
1 April 2011
Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned…
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus…
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
1 February 2011
This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point…
Priority Review Vouchers to Encourage Innovation for Neglected Diseases
1 January 2011
Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under…
Seminar Briefing on Science Policy
23 December 2010
At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review…
Report on Orphan Drugs Released
9 December 2010
OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal…